In vitro evaluation of the activity of terpenes and cannabidiol against human coronavirus E229

Lior Chatow*, Adi Nudel, Iris Nesher, David Hayo Hemo, Perri Rozenberg, Hanna Voropaev, Ilan Winkler, Ronnie Levy, Zohar Kerem, Zohara Yaniv, Nadav Eyal

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

21 Scopus citations

Abstract

The activity of a new, terpene-based formulation, code-named NT-VRL-1, against Human Coronavirus (HCoV) strain 229E was evaluated in human lung fibroblasts (MRC-5 cells), with and without the addition of cannabidiol (CBD). The main constituents in the terpene formulation used for the experiment were beta caryophyllene, eucalyptol, and citral. The tested formulation exhibited an antiviral effect when it was pre-incubated with the host cells prior to virus infection. The combination of NT-VRL-1 with CBD potentiated the antiviral effect better than the positive controls pyrazofurin and glycyrrhizin. There was a strong correlation between the quantitative results from a cell-viability assay and the cytopathic effect seen under the microscope after 72 h. To the best of our knowledge, this is the first report of activity of a combination of terpenes and CBD against a coronavirus.

Original languageAmerican English
Article number290
JournalLife
Volume11
Issue number4
DOIs
StatePublished - Apr 2021
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.

Keywords

  • Antiviral
  • CBD
  • COVID-19
  • Cannabis
  • HCoV-229E
  • Terpenes

Fingerprint

Dive into the research topics of 'In vitro evaluation of the activity of terpenes and cannabidiol against human coronavirus E229'. Together they form a unique fingerprint.

Cite this